Earnings Call Summary | Exagen(XGN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Exagen(XGN.US) Q1 2024 Earnings Conference
The following is a summary of the Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript:
以下是Exagen, Inc.（XGN）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Exagen reported Q1 2024 total revenue of $14.4 million, driven by a strong increase in AVISE CTD ASP.
The trailing 12-month ASP is now $377 per test, up 35% from a year ago.
Adjusted EBITDA for the first quarter was a negative $2 million, a significant improvement over the same period last year.
Gross margin improved to 59.6% in Q1 2024 from 47.2% in Q1 2023, primarily due to increased ASP.
Full-year 2024 revenue guidance has been increased from around $54 million to at least $55 million, and adjusted EBITDA will be better than the previously estimated negative $20 million, now expected to be better than negative $18 million.
Exagen報告稱，2024年第一季度總收入爲1,440萬美元，這得益於AVISE CTD ASP的強勁增長。
過去12個月的ASP現在爲每次測試377美元，比去年同期增長了35％。
第一季度調整後的息稅折舊攤銷前利潤爲負200萬美元，與去年同期相比大幅改善。
毛利率從2023年第一季度的47.2％提高到2024年第一季度的59.6％，這主要是由於ASP的增加。
2024年全年收入預期已從約5400萬美元提高至至少5500萬美元，調整後的息稅折舊攤銷前利潤將好於先前估計的負2,000萬美元，目前預計將好於負1,800萬美元。
Business Progress:
業務進展：
AVISE CTD test volume in Q1 was just over 30,000, essentially flat from Q4 2023, but a monthly increase is expected to continue into Q2.
Exagen will add three T-cell markers for SLE and new markers for rheumatoid arthritis to the AVISE CTD offering in Q4 2024, promising financial performance improvement and product enhancement.
The commercial team is preparing to launch the new markers and their laboratory is working to meet the operational requirements for offering the new markers at scale.
No major hurdles are expected from FDA's new rule on lab-developed tests since Exagen is CLIA, CAP, and New York State certified, with multiple assays already FDA-approved.
Exagen reduced operating territories from 63 to 40 in December 2022 and recorded increased sales productivity, with record volume in Q1 and Q2 2023.
第一季度的AVISE CTD測試量剛剛超過3萬個，與2023年第四季度相比基本持平，但預計月度增長將持續到第二季度。
Exagen將於2024年第四季度在AVISE CTD產品中增加三種用於系統性紅斑狼瘡的T細胞標誌物和類風溼關節炎的新標誌物，承諾財務業績改善和產品改進。
商業團隊正準備推出新標記，他們的實驗室正在努力滿足大規模提供新標記物的運營要求。
由於Exagen已獲得CLIA、CAP和紐約州認證，而且多項檢測已獲得美國食品藥品管理局的批准，因此預計FDA關於實驗室開發的測試的新規定不會有重大障礙。
2022年12月，Exagen將運營區域從63個減少到40個，銷售生產率有所提高，2023年第一季度和第二季度的銷量創歷史新高。
More details: Exagen IR
更多詳情： Exagen 紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。